论文部分内容阅读
目的:探讨人参皂苷Rg3联合紫杉醇是否具有协同抗胃癌细胞增殖的作用。方法:将人胃癌BGC—823细胞裸鼠移植瘤动物模型,随机分为4组(每组10只):人参皂苷Rg3组[GS-Rg3:10mg/(kg.d)灌胃],紫杉醇组(紫杉醇10mg/kg腹腔内注入,每周2次),联合组(人参皂苷Rg3+紫杉醇,用法同上),对照组(生理盐水组)。连续用药3周。用药结束后脱颈处死裸鼠,统计各组抑瘤率;免疫组化检测增殖细胞核抗原(PCNA)。结果:联合组(人参皂苷Rg3+紫杉醇)抑瘤率明显大于人参皂苷Rg3组和紫杉醇组(P<0.01);联合组增殖细胞核抗原(PCNA)活性最低,与人参皂苷Rg3组、紫杉醇组比较有显著差异(P<0.01和P<0.05)。结论:人参皂苷Rg3联合紫杉醇能协同抗胃癌细胞增殖,抑制肿瘤的生长。
Objective: To investigate whether ginsenoside Rg3 combined with paclitaxel has synergistic effect on the proliferation of gastric cancer cells. Methods: The animal model of human gastric cancer BGC-823 cells transplanted in nude mice was randomly divided into 4 groups (10 in each group): ginsenoside Rg3 group [intragastric administration of GS-Rg3: 10 mg / (kg.d) (Paclitaxel 10mg / kg intraperitoneal injection, twice a week), combined group (ginsenoside Rg3 + paclitaxel, used above), the control group (saline group). Continuous medication for 3 weeks. The nude mice were sacrificed after the treatment, and the inhibitory rate of tumor was calculated. The proliferating cell nuclear antigen (PCNA) was detected by immunohistochemistry. Results: The inhibitory rate of the combination group (ginsenoside Rg3 + paclitaxel) was significantly higher than that of the ginsenoside Rg3 group and the paclitaxel group (P <0.01). The activity of PCNA in the combined group was the lowest, which was significantly higher than that of the ginsenoside Rg3 group and the paclitaxel group Difference (P <0.01 and P <0.05). Conclusion: Ginsenoside Rg3 combined with paclitaxel can synergistically inhibit the proliferation of gastric cancer cells and inhibit tumor growth.